Evidence map›Paper›PMID 37005259›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Immunoglobulin G4-related Hepatopathy after COVID-19 Vaccination.

Masahiro Kuno, Naoki Sawa, Hiroki Mizuno, Yuki Oba, Daisuke Ikuma, Akinari Sekine, Masayuki Yamanouchi, Eiko Hasegawa, Tatsuya Suwabe, Satoshi Saito and 4 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Masahiro KunoDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Naoki SawaDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Hiroki MizunoDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Yuki ObaDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Daisuke IkumaDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Akinari SekineDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Masayuki YamanouchiDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Eiko HasegawaDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Tatsuya SuwabeDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Satoshi SaitoDepartment of Hepatology, Toranomon Hospital, Japan.
Kei KonoDepartment of Pathology, Toranomon Hospital, Japan.
Keiichi KinowakiDepartment of Pathology, Toranomon Hospital, Japan.
Kenji NotoharaDepartment of Anatomic Pathology, Kurashiki Central Hospital, Japan.
Yoshifumi UbaraDepartment of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.
Toranomon Hospital · JPKurashiki Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 84-year-old woman with IgG4-related disease presented with jaundice and liver dysfunction after coronavirus disease 2019 (COVID-19) vaccination. Serum IgG4 levels were elevated. Diagnostic imaging showed no stenotic lesions in the bile ducts. A liver biopsy was performed because of the enlarged liver. Infiltration of IgG4-positive plasma cells, which accounted for approximately 74% of total plasma cells, was found in the portal area, but there was no evidence of periportal hepatitis, and inflammatory cell infiltration into the lobular space was minimal. IgG4-related hepatopathy was diagnosed. The patient achieved spontaneous remission with no treatment and only follow-up and remains under observation at the time of writing.

Indexed as

COVID-19COVID-19 VaccinesImmunoglobulin G4-Related DiseaseLiver DiseasesAged, 80 and overFemaleHumansImmunoglobulin GCOVID-19 VaccinesImmunoglobulin GCOVID-19 vaccinationIgG4-related hepatopathy

Identifiers

PMID37005259
PMCPMC10400404
OpenAlexW4361853850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.